Stock CABA CABALETTA BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Real-time Estimate Cboe BZX
Other stock markets
 12:02:13 28/06/2024 am IST 		5-day change 1st Jan Change
7.225 USD -0.48% Intraday chart for Cabaletta Bio, Inc. -14.17% -68.50%
14/06 Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday MT
14/06 Sector Update: Health Care MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
GL
Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
AQ
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
GL
Cabaletta Bio : Corporate Presentation
PU
Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GL
Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
AQ
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
AQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
GL
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
GL
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
GL
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
AQ
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
GL
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
GL
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
BU
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CABA Stock
  4. News Cabaletta Bio, Inc.
  5. Press Releases